Simranjit Singh

Simran Singh is currently the CEO of Guardant Health AMEA, a precision oncology company that is a pioneer in comprehensive genomic profiling (liquid biopsies). The company has a vast portfolio of diagnostic tests across the continuum of cancer, from late-stage cancer to recurrence monitoring to early cancer detection. Guardant Health AMEA has a presence across 41 countries in Asia, Middle East and Africa. Prior to Guardant Health, Simran was the Vice President of the Global Medical Devices & Diagnostics division and Head of Strategic Planning Asia for IQVIA, a global CRO where he was instrumental in driving IQVIA’s growth strategy for Asia Pacific and accelerating revenue growth.

Please note that speakers provide their own biographies and headshots. Biographies represent the role of the person at the time of their engagement and are not independently verified by the Milken Institute.